Skip to main content
Top
Published in: The European Journal of Health Economics 2/2006

01-07-2006 | Original Paper

Costs and quality of life of multiple sclerosis in the United Kingdom

Authors: Gisela Kobelt, Jenny Berg, P. Lindgren , J. Kerrigan, N. Russell, R. Nixon

Published in: The European Journal of Health Economics | Special Issue 2/2006

Login to get access

Abstract

This cost-of-illness analysis for the United Kingdom is part of a Europe-wide study on the costs of multiple sclerosis (MS). The objective was to analyze the costs and quality of life (utility) related to the level of disease severity. People with MS from a database administered by a UK charity (the MS Trust) were asked to participate in the survey by answering a postal questionnaire. In addition to details on the disease (type of disease, relapses, level of functional disability), the questionnaire asked for information on all resource consumption, medical, non-medical, work absence and informal care as well as utility. The response rate was 19%, and a total of 2048 people were included. The mean age of the cohort was 51 years, and 23% of people were ≥60 years of age. Disease severity was concentrated in people with moderately severe MS (Expanded Disability Status Scale [EDSS] score of 4 to 6.5), with 21, 60 and 19% of people reporting mild, moderate and severe disease, respectively. Costs and utility are highly correlated with disease severity. Mean annual costs for all people in the study increase from approximately £ 12.000 at an EDSS score <4 to almost £ 60.000 at an EDSS score ≥7. In particular, employment rates are reduced from 82% in early disease to 2% at an EDSS score of 8, while the costs of inpatient care, investments, informal care and productivity losses increase by more than tenfold between an EDSS score of 0-1 and a score ≥7. Utility decreases from 0.92 at an EDSS score of 0 to a state worse than death in the most severe state (–0.18 at an EDSS score of 9). Compared to the results in an earlier cost study in the United Kingdom using a comparable methodology, costs have substantially increased, by roughly 40%. Part of the increase is due to a higher use of disease-modifying drugs and, possibly linked with this, a higher use of ambulatory care and services. Another part of the increase is most likely due to an increased age in the current sample, with more patients on early retirement due to MS and more intense use of informal care. However, another reason may lie in the methodology, e.g. different unit costs or differences in the sample distribution, despite a similar mean EDSS score of 5.1.
Literature
1.
go back to reference Pugliatti M, Rosati R, Carton H et al. (2006) The prevalence and incidence of multiple sclerosis in Europe. Eur J Neurol 13: 1–23CrossRef Pugliatti M, Rosati R, Carton H et al. (2006) The prevalence and incidence of multiple sclerosis in Europe. Eur J Neurol 13: 1–23CrossRef
2.
go back to reference Richards R, Sampson F, Beard S, Tappenden P (2002) A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol Assess 6: 1–73 Richards R, Sampson F, Beard S, Tappenden P (2002) A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol Assess 6: 1–73
3.
go back to reference Kobelt G, Lindgren P, Parkin D, Jönsson B (2000) Costs and quality of life in multiple sclerosis. A cross-sectional observational study in the United Kingdom. SEE/EFI Working Paper Series in Economics and Finance No. 399. Stockholm School of Economics; Stockholm, Sweden Kobelt G, Lindgren P, Parkin D, Jönsson B (2000) Costs and quality of life in multiple sclerosis. A cross-sectional observational study in the United Kingdom. SEE/EFI Working Paper Series in Economics and Finance No. 399. Stockholm School of Economics; Stockholm, Sweden
4.
go back to reference Swingler R, Compston D (1992) The morbidity of multiple sclerosis. Q J Med 83: 325–337PubMed Swingler R, Compston D (1992) The morbidity of multiple sclerosis. Q J Med 83: 325–337PubMed
5.
go back to reference Mcdonnell G, Hawkins S (2001) An assessment of the spectrum of disability and handicap in multiple sclerosis: a population based study. Mult Scler 7: 111–117CrossRefPubMed Mcdonnell G, Hawkins S (2001) An assessment of the spectrum of disability and handicap in multiple sclerosis: a population based study. Mult Scler 7: 111–117CrossRefPubMed
6.
go back to reference O’Brien B (1987) Multiple sclerosis. Office of Health Economics, London, UK O’Brien B (1987) Multiple sclerosis. Office of Health Economics, London, UK
7.
8.
go back to reference The EuroQol Group (1990) EuroQol – a new facility for the measurement of health-related quality of life. Health Policy 16: 199–208CrossRefPubMed The EuroQol Group (1990) EuroQol – a new facility for the measurement of health-related quality of life. Health Policy 16: 199–208CrossRefPubMed
9.
go back to reference Dolan P, Gudex C, Kind P, Williams A (1995) A social tariff for EuroQol: results from a UK general population survey. Discussion Paper 138 (York, Centre for Health Economics, University of York) Dolan P, Gudex C, Kind P, Williams A (1995) A social tariff for EuroQol: results from a UK general population survey. Discussion Paper 138 (York, Centre for Health Economics, University of York)
10.
go back to reference Holmes J, Madgwick T, Bates D (1995) The cost of multiple sclerosis. Br J Med Econ 8: 181–193 Holmes J, Madgwick T, Bates D (1995) The cost of multiple sclerosis. Br J Med Econ 8: 181–193
11.
go back to reference Blumhardt L, Wood C (1996) The economics of multiple sclerosis: a cost of illness study. Brit J Med Econ 8: 99–118 Blumhardt L, Wood C (1996) The economics of multiple sclerosis: a cost of illness study. Brit J Med Econ 8: 99–118
12.
go back to reference Murphy N, Confavreux C, Haas J et al. (1998) Quality of life in multiple sclerosis in France, Germany, and the United Kingdom. Cost of Multiple Sclerosis Study Group. J Neurol Neurosurg Psychiatry 65: 460–466 PubMed Murphy N, Confavreux C, Haas J et al. (1998) Quality of life in multiple sclerosis in France, Germany, and the United Kingdom. Cost of Multiple Sclerosis Study Group. J Neurol Neurosurg Psychiatry 65: 460–466 PubMed
Metadata
Title
Costs and quality of life of multiple sclerosis in the United Kingdom
Authors
Gisela Kobelt
Jenny Berg
P. Lindgren
J. Kerrigan
N. Russell
R. Nixon
Publication date
01-07-2006
Publisher
Springer-Verlag
Published in
The European Journal of Health Economics / Issue Special Issue 2/2006
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-006-0380-z

Other articles of this Special Issue 2/2006

The European Journal of Health Economics 2/2006 Go to the issue